Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board
- Futures dip after S&P 500, Dow hit record closing highs
- Bitcoin (BTC) Price Fell 20% Off the Highs Over the Weekend as Markets Got 'Too Excited' About Coinbase (COIN), Says Mike Novogratz
- UK to Intervene on National Security Grounds on NVIDIA (NVDA) and Arm Deal
- GameStop (GME) announces George Sherman will be stepping down as CEO
- Dollar slumps to 6-week low, Bitcoin steadies after weekend drop
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Company's Scientific Advisory Board.
Dr. Renshaw is a healthcare industry executive and Oncologist-Hematologist drug developer with several decades of oncology drug development experience. He has provided medical and scientific expertise ranging from early-stage pre-clinical drug development to presiding over dozens of successful U.S. investigational new drug applications and European Medical Agency new drug submissions of which some have resulted in successful new drug applications.
Dr. Renshaw is currently the Chief Medical Officer of Zhejiang DTRM Biopharma Co. Ltd. Previous roles included Medical Oncology Director at Eisai; Global Executive Director Level II, Oncology and Hematology R&D at Celgene Corporate; Executive Director at Celsion Corporation and Global Clinical Lead; and Clinical Pharm Lead at Bayer Health Care Corporation. Dr. Renshaw participates in a number of oncology industry committees and task forces.
"We are very excited to welcome Dr. Renshaw to the Company's Scientific Advisory Board, said Dr. Heman Chao, Helix's Chief Executive and Science Officer. "Dr. Renshaw brings a wealth of experience in oncology drug development and medical expertise to Helix. I look forward to working with the Scientific Advisory Board in continuing the advancement of L-DOS47 in the clinic."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the Toronto Stock Exchange under the symbol "HBP".
More information can be found on the Company's website at www.helixbiopharma.com
Forward-Looking Statements and Risks and Uncertainties
This news release may contain forward-looking statements with respect to Helix, its operations, strategy, financial performance and condition, including its activities relating to its drug development program, any anticipated timelines for the commencement or completion of certain activities such as the closing of the transactions described herein, raising sufficient capital, merger and acquisition activity, listing on a U.S. exchange and other information in future periods. These statements generally can be identified by use of forward-looking words such as "aims", "transform", "should", "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of discussed herein could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations, including: (i) Helix's ability to operate as a going concern being dependent mainly on securing sufficient additional financing in order to fund its ongoing research and development and other operating activities; (ii) the generally inherent uncertainty involved in scientific research and drug development and those specific to Helix's pre-clinical and clinical development programs (DOS47, L-DOS47 and V-DOS47); (iii) that any transactions contemplated herein are completed; and (iv) those risks and uncertainties affecting Helix as more fully described in Helix's most recent Annual Information Form, which is available at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors and assumptions are applied in making the forward-looking statements, including, without limitation, that the conditions to closing of the transactions described herein will be satisfied or waived, that sufficient financing will be obtained in a timely manner to allow Helix to continue operations and implement its clinical trials in the manner and on the timelines anticipated and that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Phone: +1 (905) 841-2300
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (917) 385-2160
SOURCE: Helix BioPharma Corp.
View source version on accesswire.com:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herman Miller (MLHR) to Acquire Knoll (KNL) for $1.8 Billion in Cash in Stock
- Virtana Achieves 63% Sales Growth in Q1 2021 Over Q1 2020; Exceeds Sales Goals Two Quarters in a Row
- Fresh on the Heels of WOWorks Acquisition, Saladworks and Frutta Bowls Team Up with Combo Kitchen
Create E-mail Alert Related CategoriesAccesswire, Press Releases
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!